A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

GSK Investigational Site, Ciudad Autonoma de Bueno

GSK Investigational Site, Milan

GSK Investigational Site, Milan

GSK Investigational Site, Hamburg

GSK Investigational Site, Madrid

GSK Investigational Site, Madrid

GSK Investigational Site, Huntersville

GSK Investigational Site, Charlotte

GSK Investigational Site, Málaga

GSK Investigational Site, Murcia

GSK Investigational Site, Pensacola

GSK Investigational Site, Orlando

GSK Investigational Site, Fort Lauderdale

GSK Investigational Site, Ft. Pierce

GSK Investigational Site, La Laguna-Tenerife

GSK Investigational Site, Granada

GSK Investigational Site, Birmingham

GSK Investigational Site, Düsseldorf

GSK Investigational Site, Seville

GSK Investigational Site, Orléans

GSK Investigational Site, Berkley

GSK Investigational Site, Frankfurt am Main

GSK Investigational Site, Kansas City

GSK Investigational Site, Omaha

GSK Investigational Site, Foggia

GSK Investigational Site, Paris

GSK Investigational Site, Paris

GSK Investigational Site, Dallas

GSK Investigational Site, Paris

GSK Investigational Site, Fort Worth

GSK Investigational Site, Beaumont

GSK Investigational Site, München

GSK Investigational Site, Henderson

GSK Investigational Site, Bakersfield

GSK Investigational Site, Créteil

GSK Investigational Site, Temuco

GSK Investigational Site, Providencia

GSK Investigational Site, La Cisterna

GSK Investigational Site, Santiago

GSK Investigational Site, Buenos Aires

GSK Investigational Site, Mar del Plata

GSK Investigational Site, Rosario

GSK Investigational Site, Hamilton

GSK Investigational Site, Montreal

GSK Investigational Site, Roma

GSK Investigational Site, Ponce

GSK Investigational Site, Almería